{"search_session":{},"preferences":{"l":"ar","queryLanguage":"ar"},"patentId":"188-020-386-940-835","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"188-020-386-940-835","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8904,"type":"PATENT","title":"Univ Washington Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15386,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8219,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ Washington', \"Washington Univ\", \"University of Washington\", \" Washington University\", \"Univ Washington NOT state\", \" Univ Washington NOT state NOT George\".
Select more for logical variants
Add to collection
Total patent: 10892
Search applicants and owners= \"Univ Washington', \"Washington Univ\", \"University of Washington\", \" Washington University\", \"Univ Washington NOT state\", \" Univ Washington NOT state NOT George\".
Select more for logical variants
Add to collection
Total patent: 10892
a tafazzin peptide; and\n
a cellular permeability peptide."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the tafazzin peptide is coupled to the cellular permeability peptide through a polypeptide linker."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 2, comprising a peptide selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the tafazzin peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the cellular permeability peptide is an antennapedia permeability peptide."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 5, wherein the antennapedia permeability peptide comprises SEQ ID NO: 6."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the cellular permeability peptide is an HIV Tat permeability peptide."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 7, wherein the HIV Tat permeability peptide comprises SEQ ID NO: 7."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the cellular permeability peptide is a cardiac targeting peptide (CTP)."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 9, wherein the CTP comprises SEQ ID NO: 8."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 1, wherein the cellular permeability peptide is a Kaposi FGF4-permeability peptide."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The isolated and purified fusion protein of claim 11, wherein the Kaposi FGF4-permeability peptide comprises SEQ ID NO: 9."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency, comprising:\n
administering to the patient an effective amount of a pharmaceutical composition comprising:\n\na fusion protein comprising a tafazzin peptide and a cellular permeability peptide; and\na pharmaceutically acceptable carrier\n
to reduce a pathological effect or symptom of the disorder associated with the tafazzin deficiency or the remodeled cardiolipin deficiency."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the tafazzin deficiency or the remodeled cardiolipin deficiency is associated with a tafazzin gene (TAZ) mutation."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the disorder associated with a tafazzin deficiency or the remodeled cardiolipin deficiency is Barth syndrome."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the tafazzin peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3, wherein the cellular permeability peptide is selected from at least one of an antennapedia permeability peptide, an HIV Tat permeability peptide, a cardiac targeting peptide (CTP), or a Kaposi FGF4-permeability peptide."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating a patient having or at risk of developing, Barth syndrome, comprising:\n
administering to the patient an effective amount of a pharmaceutical composition comprising:\n\na fusion protein comprising a tafazzin peptide and a permeability peptide; and\na pharmaceutically acceptable carrier\n
to reduce a pathological effect or symptom of Barth syndrome, or to reduce the risk of developing Barth syndrome."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the fusion protein is selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the cellular permeability peptide comprises a peptide selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the fusion protein comprises a peptide selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the tafazzin peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the cellular permeability peptide is an antennapedia permeability peptide."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the antennapedia permeability peptide comprises SEQ ID NO: 6."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the cellular permeability peptide is an HIV Tat permeability peptide."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 25, wherein the HIV Tat permeability peptide comprises SEQ ID NO: 7."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the cellular permeability peptide is a cardiac targeting peptide (CTP)."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 27, wherein the CTP comprises SEQ ID NO: 8."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the cellular permeability peptide is a Kaposi FGF4-permeability peptide."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 29, wherein the Kaposi FGF4-permeability peptide comprises SEQ ID NO: 9."],"number":30,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}